Breaking News Instant updates and real-time market news.

ICPT

Intercept

$70.79

0.68 (0.97%)

07:04
04/13/18
04/13
07:04
04/13/18
07:04

Intercept announces data from liver biopsy substudy of POISE Phase 3 trial

Intercept Pharmaceuticals announced clinical data from a liver biopsy-based substudy from the POISE Phase 3 trial suggesting that long-term OCA treatment in patients with PBC was associated with reversal or stabilization of fibrosis and cirrhosis. The data are being presented at the International Liver Congress 2018, the 53rd Annual Meeting of the European Association for the Study of the Liver, in Paris, France, from April 11-15, 2018. OCA is not currently indicated for the reversal of fibrosis or cirrhosis in patients with PBC. Prior longitudinal biopsy studies have shown that patients who are not treated with, or have an inadequate response to, ursodeoxycholic acid, the current standard of care, are at significantly higher risk of fibrosis progression, liver failure, transplant and death. Liver biopsy is not the standard of care in PBC and difficult to obtain in clinical trials. In this voluntary substudy of the POISE Phase 3 trial, paired biopsies adequate for analysis were obtained for 13 patients, all of whom had liver fibrosis or cirrhosis at baseline. After three years of treatment with OCA, the majority of patients improved or maintained histological fibrosis stage, while two patients experienced one stage progression. Of the four patients with cirrhosis at baseline, all showed reversal by at least one stage, and three improved to fibrosis without cirrhosis. Pruritus is the most common symptom in patients with PBC and was also the most common adverse event in the POISE Phase 3 substudy. Nine patients experienced pruritus in the substudy, an incidence consistent with the rate observed in the broader study population. A total of five serious adverse events in five patients were reported. All serious adverse events were considered unlikely to be related, or not related, to OCA. A separate poster, "Durable Response in the Markers of Cholestasis through 36 Months of Open-Label Extension Study of Obeticholic Acid in Primary Biliary Cholangitis," presented at the International Liver Congress provided additional results from the open-label extension of the POISE trial. Sustained improvements in ALP were observed through three years of OCA therapy, with similar improvements seen for GGT, ALT and AST. Mean total bilirubin remained below baseline throughout the three-year open-label period. The most common adverse event observed with OCA therapy was pruritus, resulting in the discontinuation of seven patients during the open-label extension treatment phase. An additional poster, "Change in Bilirubin with Obeticholic Acid Treatment in Primary Biliary Cholangitis Patients with High Baseline Bilirubin: A Retrospective Analysis of POISE, 201, and 202," assessed changes in total bilirubin observed in the POISE Phase 3 trial and two Phase 2 trials. The analysis, which included patients with total bilirubin greater than or equal to0.67 times the upper limit of normal at baseline, found that total bilirubin increased after 12 months of placebo treatment and decreased after 12 months of treatment with OCA. In the double-blind phase of POISE, 14% of placebo-treated and 78% of OCA-treated patients with abnormal total bilirubin at baseline attained normal levels after 12 months. Further, of 10 placebo-treated and 20 OCA-treated patients with normal total bilirubin at baseline, 60% of placebo-treated and 15% of OCA-treated patients worsened to abnormal total bilirubin after 12 months. Per EASL clinical guidelines, increasing bilirubin levels - even within the normal range - indicate progressive disease and are strongly associated with adverse clinical outcomes.

  • 13

    Apr

  • 20

    Apr

  • 08

    May

  • 21

    May

ICPT Intercept
$70.79

0.68 (0.97%)

02/07/18
GSCO
02/07/18
DOWNGRADE
Target $45
GSCO
Sell
Intercept downgraded to Sell from Neutral at Goldman Sachs
Goldman Sachs analyst Salveen Richter downgraded Intercept Pharmaceuticals to Sell and cut his price target for the shares to $45 from $74. The analyst sees a lack of catalyats to move the stock higher. Intercept closed yesterday up $2.08 to $60.82.
02/12/18
DBAB
02/12/18
NO CHANGE
Target $103
DBAB
Buy
Intercept study initiation a positive, says Deutsche Bank
Deutsche Bank analyst Navin Jacob views the initiation of the Reverse NASH trial is a positive for Intercept Pharmaceuticals, saying it "puts to rest any lingering bear arguments that OCA is not safe." The trial, if successful, presents potential upside to numbers, Jacob tells investors in a research note. He keeps a Buy rating on the shares with a $103 price target.
02/13/18
WELS
02/13/18
NO CHANGE
Target $57
WELS
Market Perform
Intercept price target lowered to $57 from $62 at Wells Fargo
Wells Fargo analyst Jim Birchenough lowered his price target for Intercept to $57 from $62 following his most recent review of the FDA AERS Safety Database for marketed bile acid analog OCALIVA, and significant increase in patient deaths in Q4. While Intercept has highlighted an independent safety review of post-marketing safety events cited in a September, 2017 FDA Drug Safety Communication, the analyst believes that significant increase in patient deaths in Q4 is concerning and the rate is above that predicted for the approved OCALIVA patient population by his estimate. Birchenough reiterates a Market Perform rating on the shares.
03/28/18
LEER
03/28/18
NO CHANGE
Target $16
LEER
Outperform
More differentiating data at EASL can continue CymaBay momentum, says Leerink
Leerink analyst Joseph Schwartz expects a 6-month Phase 2 study update for CymaBay's (CBAY) seladelpar in primary biliary cholangitis to be reported at the International Liver Congress. The analyst notes CymaBay stock has enjoyed strong momentum since the preliminary 12-week data and he remains optimistic that seladelpar's profile will continue to look differentiated from Intercept's (ICPT) Ocaliva when it comes to safety/tolerability and efficacy in the second-line PBC treatment setting. The analyst reiterates an Outperform rating and $16 price target on CymaBay's shares.

TODAY'S FREE FLY STORIES

FCAU

Fiat Chrysler

$19.33

-0.195 (-1.00%)

13:14
07/21/18
07/21
13:14
07/21/18
13:14
Hot Stocks
Fiat names Jeep head as CEO as Marchionne's health worsens »

In a statement, Fiat…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RACE

Ferrari

$139.98

-2.65 (-1.86%)

, PM

Philip Morris

$84.31

3.41 (4.22%)

13:10
07/21/18
07/21
13:10
07/21/18
13:10
Hot Stocks
Ferrari to name former Philip Morris chairman as CEO »

The Board of Directors of…

RACE

Ferrari

$139.98

-2.65 (-1.86%)

PM

Philip Morris

$84.31

3.41 (4.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

AMZN

Amazon.com

$1,813.84

0.99 (0.05%)

, TM

Toyota

$131.87

0.11 (0.08%)

12:51
07/21/18
07/21
12:51
07/21/18
12:51
Periodicals
Amazon, others working to counter Trump's tariff plans, Reuters says »

Big companies in the…

AMZN

Amazon.com

$1,813.84

0.99 (0.05%)

TM

Toyota

$131.87

0.11 (0.08%)

AA

Alcoa

$40.32

-1.36 (-3.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 16

    Aug

FCAU

Fiat Chrysler

$19.33

-0.195 (-1.00%)

12:47
07/21/18
07/21
12:47
07/21/18
12:47
Periodicals
Fiat Chrysler's Sergio Marchionne to step down, NYTimes reports »

Fiat Chrysler's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCAU

Fiat Chrysler

$19.33

-0.195 (-1.00%)

12:43
07/21/18
07/21
12:43
07/21/18
12:43
Periodicals
Fiat Chrysler to name Jeep's Manley as CEO, Reuters reports »

Fiat Chrysler has named…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BABA

Alibaba

$187.21

-0.14 (-0.07%)

, TCEHY

Tencent

$0.00

(0.00%)

12:40
07/21/18
07/21
12:40
07/21/18
12:40
Periodicals
Alibaba, Tencent in talks to buy stake in WPP's Chinese unit, Reuters says »

Alibaba (BABA) and…

BABA

Alibaba

$187.21

-0.14 (-0.07%)

TCEHY

Tencent

$0.00

(0.00%)

WPP

WPP

$76.08

1.52 (2.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

AMZN

Amazon.com

$1,813.84

0.99 (0.05%)

, NFLX

Netflix

$361.33

-2.81 (-0.77%)

11:24
07/21/18
07/21
11:24
07/21/18
11:24
Periodicals
Amazon, Netflix to face tighter capital markets, Barron's says »

Since the Great…

AMZN

Amazon.com

$1,813.84

0.99 (0.05%)

NFLX

Netflix

$361.33

-2.81 (-0.77%)

TSLA

Tesla

$313.49

-6.85 (-2.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 01

    Aug

  • 07

    Aug

  • 16

    Aug

AB

AllianceBernstein

$29.90

-0.05 (-0.17%)

, BLK

BlackRock

$503.01

-1.42 (-0.28%)

11:17
07/21/18
07/21
11:17
07/21/18
11:17
Periodicals
BlackRock, T. Rowe Price look like bargains, Barron's says »

With shares of many…

AB

AllianceBernstein

$29.90

-0.05 (-0.17%)

BLK

BlackRock

$503.01

-1.42 (-0.28%)

BEN

Franklin Resources

$31.99

-0.28 (-0.87%)

IVZ

Invesco

$25.46

-0.245 (-0.95%)

LM

Legg Mason

$33.37

-0.13 (-0.39%)

TROW

T. Rowe Price

$119.87

-0.85 (-0.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 26

    Jul

  • 27

    Jul

ALV

Autoliv

$104.08

-0.57 (-0.54%)

, VNE

Veoneer

$50.81

-1.81 (-3.44%)

11:12
07/21/18
07/21
11:12
07/21/18
11:12
Periodicals
Automotive spinoffs offer exposure to autonomous, electric future, Barron's says »

Last month, Autoliv (ALV)…

ALV

Autoliv

$104.08

-0.57 (-0.54%)

VNE

Veoneer

$50.81

-1.81 (-3.44%)

DLPH

Delphi Technologies

$44.78

-0.355 (-0.79%)

APTV

Aptiv

$92.95

-2.02 (-2.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

  • 08

    Aug

DDAIF

Daimler AG

$0.00

(0.00%)

, FCAU

Fiat Chrysler

$19.33

-0.195 (-1.00%)

07:58
07/21/18
07/21
07:58
07/21/18
07:58
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$19.33

-0.195 (-1.00%)

F

Ford

$10.56

-0.115 (-1.08%)

GM

General Motors

$39.39

0.08 (0.20%)

HMC

Honda

$29.18

-0.19 (-0.65%)

NSANY

Nissan

$0.00

(0.00%)

TM

Toyota

$131.87

0.11 (0.08%)

VLKAY

Volkswagen

$0.00

(0.00%)

GOOG

Alphabet

$1,184.77

-2.37 (-0.20%)

GOOGL

Alphabet Class A

$1,198.05

-1.21 (-0.10%)

PFE

Pfizer

$37.33

-0.03 (-0.08%)

NVS

Novartis

$82.28

1.47 (1.82%)

RHHBY

Roche

$0.00

(0.00%)

SNY

Sanofi

$42.38

0.44 (1.05%)

BA

Boeing

$354.92

-0.57 (-0.16%)

MRK

Merck

$62.51

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jul

  • 23

    Jul

  • 23

    Jul

  • 25

    Jul

  • 25

    Jul

  • 27

    Jul

  • 08

    Aug

  • 15

    Aug

  • 22

    Aug

  • 10

    Sep

  • 10

    Sep

  • 18

    Sep

  • 20

    Oct

  • 23

    Oct

  • 28

    Oct

  • 28

    Oct

  • 28

    Jan

  • 16

    Feb

  • 22

    Mar

ACN

Accenture

$166.47

-0.47 (-0.28%)

, EADSY

Airbus

$0.00

(0.00%)

04:55
07/21/18
07/21
04:55
07/21/18
04:55
Conference/Events
Farnborough International to hold an airshow »

Farnborough International…

ACN

Accenture

$166.47

-0.47 (-0.28%)

EADSY

Airbus

$0.00

(0.00%)

ATI

Allegheny Technologies

$26.65

0.08 (0.30%)

BAESY

BAE Systems

$0.00

(0.00%)

BDRBF

Bombardier

$0.00

(0.00%)

CAE

CAE

$20.96

0.17 (0.82%)

CW

Curtiss-Wright

$125.79

-0.12 (-0.10%)

DASTY

Dassault Systemes

$0.00

(0.00%)

ESLT

Elbit Systems

$118.98

0.64 (0.54%)

LMT

Lockheed Martin

$322.76

3.09 (0.97%)

BA

Boeing

$354.92

-0.57 (-0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 24

    Jul

  • 25

    Jul

  • 26

    Jul

  • 30

    Jul

  • 02

    Aug

  • 06

    Aug

  • 16

    Aug

FNWB

First Northwest Bancorp

$16.11

0.36 (2.29%)

17:48
07/20/18
07/20
17:48
07/20/18
17:48
Hot Stocks
First Northwest Bancorp names Terry Anderson chief credit officer »

First Northwest Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCX

Freeport McMoRan

$15.75

-0.05 (-0.32%)

17:42
07/20/18
07/20
17:42
07/20/18
17:42
Hot Stocks
Freeport McMoRan CAO Michael Arnold to retire »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLE

Energy Select Sector SPDR

$74.87

-0.24 (-0.32%)

, XLU

Utilities SPDR

$52.28

-0.39 (-0.74%)

17:39
07/20/18
07/20
17:39
07/20/18
17:39
General news
Week ending ETF Scorecard: Financials lead, Energy slumps »

S&P500 SECTORS:…

XLE

Energy Select Sector SPDR

$74.87

-0.24 (-0.32%)

XLU

Utilities SPDR

$52.28

-0.39 (-0.74%)

IYR

DJ US Real Estate Index Fund

$80.23

-0.68 (-0.84%)

XLP

Consumer Staples Sector SPDR

$52.84

0.3 (0.57%)

XLY

Consumer Discretionary Sector SPDR

$112.15

-0.47 (-0.42%)

XLB

S&P Select Materials SPDR

$58.31

-0.21 (-0.36%)

XLF

Financial Select Sector

$27.57

0.065 (0.24%)

XLV

Health Care Select Sector SPDR

$86.74

-0.17 (-0.20%)

XLK

Technology Select Sector SPDR

$72.55

0.01 (0.01%)

XLI

Industrial Select Sector SPDR

$74.44

-0.09 (-0.12%)

GLD

SPDR Gold Trust

$116.56

0.74 (0.64%)

SLV

iShares Silver Trust

$14.59

0.18 (1.25%)

USO

United States Oil Fund

$14.15

0.025 (0.18%)

UNG

United States Natural Gas Fund

$22.38

-0.06 (-0.27%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$85.62

0.03 (0.04%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$115.27

-0.335 (-0.29%)

TLT

iShares 20+ Year Treasury Bond Fund

$120.78

-1.46 (-1.19%)

IEF

iShares 7-10 Year Treasury Bond ETF

$102.21

-0.35 (-0.34%)

SHY

iShares 1-3 Year Treasury Bond

$83.26

-0.005 (-0.01%)

IWD

iShares Russell 1000 Value

$123.07

-0.2897 (-0.23%)

IWF

iShares Russell 1000 Growth

$149.41

-0.04 (-0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XRX

Xerox

$25.10

-0.095 (-0.38%)

, FUJIY

Fujifilm

$0.00

(0.00%)

17:25
07/20/18
07/20
17:25
07/20/18
17:25
Hot Stocks
Xerox, Centerview settle matters related to proposed Fuji tie-up »

On July 20, 2018, Xerox…

XRX

Xerox

$25.10

-0.095 (-0.38%)

FUJIY

Fujifilm

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

STON

StoneMor Partners

$3.61

-0.015 (-0.41%)

17:15
07/20/18
07/20
17:15
07/20/18
17:15
Hot Stocks
Breaking Hot Stocks news story on StoneMor Partners »

Oaktree Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEF

Telefonica

$8.70

0.07 (0.81%)

17:11
07/20/18
07/20
17:11
07/20/18
17:11
Downgrade
Telefonica rating change at Goldman Sachs »

Telefonica downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$279.71

-0.24 (-0.09%)

, USO

United States Oil Fund

$14.15

0.025 (0.18%)

17:04
07/20/18
07/20
17:04
07/20/18
17:04
General news
Weekly CFTC Commitment of Traders highlights »

S&P500 net long 5.5K…

SPY

SPDR S&P 500 ETF Trust

$279.71

-0.24 (-0.09%)

USO

United States Oil Fund

$14.15

0.025 (0.18%)

GLD

SPDR Gold Trust

$116.56

0.74 (0.64%)

FXE

Euro Currency Trust

$112.46

0.83 (0.74%)

FXC

CurrencyShares Canadian Dollar Trust

$75.17

0.81 (1.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CZWI

Citizens Community Bancorp

$14.15

(0.00%)

17:02
07/20/18
07/20
17:02
07/20/18
17:02
Syndicate
Breaking Syndicate news story on Citizens Community Bancorp »

Citizens Community…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PKD

Parker Drilling

$0.30

-0.0044 (-1.46%)

17:01
07/20/18
07/20
17:01
07/20/18
17:01
Hot Stocks
Breaking Hot Stocks news story on Parker Drilling »

Whitebox Advisors reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

RSLS

ReShape Lifesciences

$1.47

-0.02 (-1.34%)

17:00
07/20/18
07/20
17:00
07/20/18
17:00
Hot Stocks
Breaking Hot Stocks news story on ReShape Lifesciences  »

Intracoastal Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BOX

Box

$26.13

-0.26 (-0.99%)

16:57
07/20/18
07/20
16:57
07/20/18
16:57
Initiation
Box initiated at First Analysis »

Box initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALDX

Aldeyra

$7.95

-0.15 (-1.85%)

16:53
07/20/18
07/20
16:53
07/20/18
16:53
Syndicate
Breaking Syndicate news story on Aldeyra »

Aldeyra files $250M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLRE

Greenlight Capital Re

$14.00

-0.15 (-1.06%)

16:46
07/20/18
07/20
16:46
07/20/18
16:46
Hot Stocks
Greenlight Capital Re announces departure of COO »

Greenlight Capital Ry…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RVI

Retail Value

$34.56

0.2 (0.58%)

16:38
07/20/18
07/20
16:38
07/20/18
16:38
Hot Stocks
Breaking Hot Stocks news story on Retail Value »

Luxor Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.